AV22 is not a universal antiviral yet—and that distinction matters

What if one medicine could cover influenza, coronaviruses and RSV? It is an attractive idea—and exactly the kind of idea that headlines can inflate before the evidence is ready. Researchers associated with Turin and Pisa have identified AV22, a molecule reported to show antiviral activity against these respiratory viruses in laboratory experiments. That is promising. It is not yet a treatment.

The research points to a new chemical class of PDIA3 inhibitors, with AV22 as a particularly interesting candidate, according to the University of Pisa. Reports describe activity against influenza, coronaviruses and respiratory syncytial virus, or RSV, in vitro. The documentation provided only supports in vitro activity; it does not provide results from animal studies, human safety studies or clinical efficacy trials.

Broad-spectrum activity is valuable precisely because respiratory viruses are not interchangeable

Influenza, coronaviruses and RSV can produce overlapping respiratory symptoms, but they are different viruses. The CDC’s guidance on multiplex testing treats influenza viruses, SARS-CoV-2 and RSV as separate infections because identifying the culprit can help inform antiviral-treatment decisions. A single drug that worked across all three would therefore offer more than convenience: it could make early treatment less dependent on knowing which virus is circulating in a crowded winter season.

That breadth could also matter during an outbreak, when the pathogen may be unfamiliar or when testing capacity is limited. A compound aimed at a process used by host cells rather than a feature unique to one virus might, in principle, be harder for viruses to evade by changing a single viral target. That is the conceptual appeal of AV22’s reported mechanism.

But the same feature creates a central risk. A host-directed drug does not target only the virus. It intervenes in biology that belongs to the infected person as well. The scientific question is not simply whether AV22 suppresses viral replication in a dish; it is whether it can do so at a useful dose without disrupting PDIA3-related cellular functions. The documentation establishes an intriguing laboratory direction, not the answer to that safety question.

“Works against three virus groups” is a starting point, not a clinical claim

The most important correction to the current excitement is a change of verb. AV22 may inhibit influenza, coronaviruses and RSV under experimental conditions. That does not show that it prevents hospitalization, shortens illness, reduces transmission or works in people. Nor does it tell us whether the molecule reaches the right tissues, survives long enough in the body, or can be administered at a tolerable dose.

This gap is familiar in antiviral research. A 2022 open-access study on broad-spectrum influenza compounds tested dozens of molecules in hemagglutination-inhibition assays and found candidates active across three influenza strains, while also using computational modeling to examine binding. That is useful discovery work, but it illustrates how far a promising chemical signal can sit from a medicine available to patients. The study in PMC documented experimental activity, but the documentation provided does not report clinical results or approval for that compound.

The same discipline should apply here. “Broad-spectrum” describes the range of activity observed, not the reliability of the eventual therapy. The relevant evidence ladder runs from biochemical and cell experiments to animal pharmacology, toxicology, first-in-human safety, controlled efficacy trials and—only after that—real-world use. The documentation supplied supports AV22 at the in vitro stage, and no further stage can be established from those materials.

The real scandal is not that development is slow; it is that preparation is fragmented

It is tempting to frame slow antiviral development as a failure of scientific imagination. The pipeline suggests something more complicated. The INTREPID Alliance’s 5th landscape, based on information through January 2026, reports some progress but also significant gaps across antiviral research. It argues that expanding the indications of existing clinical-stage or approved medicines can be the fastest way to test possible broad-spectrum activity, while new chemical entities must be developed in parallel. Its analysis also emphasizes the attrition and long timelines built into antiviral R&D.

That is the uncomfortable lesson behind AV22. Discovering a molecule is only one part of preparedness. Researchers need sustained funding to move candidates through toxicology and trials before the next outbreak creates urgency. Regulators and health systems need plans for testing, manufacturing and access. And scientists need to evaluate activity across relevant virus families rather than celebrating a narrow laboratory result as if it were a finished public-health tool.

In our view, broad-spectrum antivirals deserve more attention, not less skepticism. Their potential payoff is unusually large: one successful medicine could be useful across seasonal disease and perhaps an emerging threat. But that very promise makes overstatement dangerous. If the public hears “one molecule against influenza, coronaviruses and RSV” and later learns that the compound failed on safety or efficacy, confidence in legitimate antiviral research takes the hit.

AV22 should therefore be treated as a candidate worth advancing, not as a breakthrough already delivered. The next meaningful headline will not be that it works in vitro. It will be evidence that the molecule is safe in people and improves outcomes in well-designed clinical trials. Until then, the sensible verdict is enthusiasm with a hard boundary: promising chemistry, unfinished medicine.